Loading
PMV Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by INTERWEST PARTNERS X LP, was filed 02 Oct 2020.
PMV Pharmaceuticals, Inc.: what insiders have been doing
PMV Pharmaceuticals, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 24 October 2026, 2 filings were filed, from 2 insiders.
Only sales appear on the open market, 1 sale in all totalling €1.3M, filed by 1 insider. Orbimed Advisors LLC filed the largest sale, €1.3M, on 27 October 2025.
With 2 filings in twelve months, the company is quieter than the median of 24 filings across the 3,167 companies we follow on the same exchange. Over the whole record (from 2020), the tally stands at 5 purchases and 180 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -77.7 m USD.
Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
293
Thresholds
n/a
Buy Volume
€38M
5 ops. · all time
Sell Volume
€53M
180 ops. · all time
Who traded when
BuySaleOrbimed Advisors LLC2 sales
David Henry Mack1 sale
Deepika Jalota1 sale
Michael Carulli1 sale
Robert Ticktin1 sale
Since the insiders bought
- -12.4%Entry US$32.95 · Close at T+365 US$28.88
- -16.1%Entry US$35.50 · Close at T+365 US$29.80
- -16.1%Entry US$35.50 · Close at T+365 US$29.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.28
Analyst consensus
5 analysts1.00/5
US$3.00Target US$4.20(+228%)US$5.00
Income statement
EBITDA-US$86.1M
Net income-US$77.7M0.0% margin
Valuation
PER (forward)-1.3x
P/Book1.0x
Beta1.35
Balance sheet & cash
Market capUS$96.7M
Total debtUS$838k
Free Cash Flow-US$73.6M
Debt / Equity0%
Profitability & ownership
ROE-70.9%
ROA-42.4%
% insiders2.4%
% institutions46.4%
Last declaration on 29 October 2025
Declarations293 total
220,643 shares@ US$1.3747.0% of flowCommon StockSEC:0001341642-25-000004:0
1,000,000 shares@ US$1.5213.4% of flowCommon StockSEC:0000947871-25-000927:0
500,000 shares@ US$1.807.9% of flowCommon StockSEC:0000947871-25-000854:0
23,151 shares@ US$1.0648100.0% of flowCommon StockSEC:0001415889-25-019386:0
58,411 shares@ US$1.06459.5% of flowCommon StockSEC:0001415889-25-019380:0
33,065 shares@ US$1.064540.3% of flowCommon StockSEC:0001415889-25-019384:0
28,249 shares@ US$1.064786.6% of flowCommon StockSEC:0001415889-25-019382:0
17,709 shares@ US$0.531.6% of flowCommon StockSEC:0001415889-25-001853:1
91,750 shares@ US$0.538.4% of flowCommon StockSEC:0001415889-25-001853:0
7,218 shares@ US$1.503613.3% of flowCommon StockSEC:0001415889-24-023313:0
2,891 shares@ US$1.503613.4% of flowCommon StockSEC:0001415889-24-023309:0
82,220 shares0Common StockSEC:0001209191-24-001995:0
163,890 shares0Common StockSEC:0001209191-24-001993:0
95,555 shares0Common StockSEC:0001209191-24-001999:0
87,786 shares@ US$2.231.8% of flowCommon StockSEC:0000947871-23-001104:0
85,307 shares0Common StockSEC:0001209191-23-054997:1
85,307 shares0Common StockSEC:0001209191-23-054997:2
198,407 shares@ US$0.5318.1% of flowCommon StockSEC:0001209191-23-054997:0
6,291 shares@ US$6.6237.4% of flowCommon StockSEC:0001209191-23-049751:0
4,104 shares@ US$6.6234.5% of flowCommon StockSEC:0001209191-23-049759:0
85,500 shares@ US$0.537.5% of flowCommon StockSEC:0001209191-23-045010:0
2,560 shares0Common StockSEC:0001209191-23-005476:0
34,050 shares0Common StockSEC:0001209191-22-049694:0
52,200 shares0Common StockSEC:0001209191-22-049692:0
26,253 shares@ US$15.934.0% of flowCommon StockSEC:0000947871-22-000675:0
25 of 293 declarations
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. (ticker: PMVP) is a U.S.-based biotechnology company listed on the NASDAQ market in the United States, focused on precision oncology. The company is developing small-molecule therapies designed to target mutations in p53, one of the most important tumor-suppressor pathways in cancer biology. Its core scientific thesis is to restore the function of mutant p53 and thereby re-enable the body’s natural anti-cancer mechanisms. PMV Pharmaceuticals was founded in 2013 by David Mack, Ph.D., Arnold Levine, Ph.D., and Thomas Shenk, Ph.D., and is headquartered in Princeton, New Jersey. ([pmvpharma.com](https://www.pmvpharma.com/?utm_source=openai))
The company’s lead clinical program is rezatapopt, a candidate designed to address tumors carrying the TP53 Y220C mutation. PMV Pharma’s development strategy is built around a tumor-agnostic approach: the drug is intended to treat cancers defined by a genetic alteration rather than by the organ of origin. In recent disclosures, management indicated that it expects to submit an NDA for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027, which places the asset in an advanced but still pre-commercial stage. Recent clinical and scientific milestones, including Phase 2 PYNNACLE interim data and a New England Journal of Medicine publication describing first-in-human data, have strengthened the company’s credibility and helped validate the scientific rationale behind its p53 platform. ([ir.pmvpharma.com](https://ir.pmvpharma.com/news-releases/news-release-details/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and/?utm_source=openai))
Read moreShow less
From a competitive standpoint, PMV Pharmaceuticals occupies a highly specialized niche. Its differentiation comes from targeting mutant p53, a historically difficult drug target, and from focusing on a clearly defined molecular subset of patients with high unmet medical need. That focus can create meaningful upside if clinical and regulatory execution remains positive, but it also means the investment case is concentrated in a small number of programs and is therefore sensitive to trial readouts, regulatory timing, and financing needs. Recent full-year and quarterly updates indicate that PMV remains a clinical-stage biotech, with capital allocation and pipeline progression centered on rezatapopt and the broader p53 platform. ([ir.pmvpharma.com](https://ir.pmvpharma.com/news-releases/news-release-details/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and/?utm_source=openai))
Geographically, PMV operates primarily from the United States, with its corporate and R&D activities centered in Princeton, New Jersey. The company also recently announced a board chair transition, underscoring an active governance phase as it advances toward key clinical and regulatory milestones. For investors in Europe seeking exposure to U.S. NASDAQ-listed biotech names, PMVP is a high-risk, high-potential precision-oncology story: scientifically differentiated, still execution-dependent, and closely tied to the outcome of rezatapopt development and eventual regulatory filing. ([ir.pmvpharma.com](https://ir.pmvpharma.com/news-releases/news-release-details/pmv-pharmaceuticals-announces-board-chair-transition/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
